Ionis Pharmaceuticals IONS Impairment of intangible assets
Impairment of intangible assets at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ImpairmentOfIntangibleAssetsFinitelived.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's impairment of intangible assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's impairment of intangible assets?
- Ionis Pharmaceuticals (IONS) reported impairment of intangible assets of $40K in Q1 2026.
- How has Ionis Pharmaceuticals's impairment of intangible assets changed year-over-year?
- Ionis Pharmaceuticals's impairment of intangible assets decreased by 34.4% year-over-year, from $61K to $40K.
- What is the long-term trend for Ionis Pharmaceuticals's impairment of intangible assets?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's impairment of intangible assets has grown at a -22.3% compound annual growth rate (CAGR), from $2.71M to $986K.
- What does impairment of intangible assets mean?
- The reduction in value of intangible assets like patents due to diminished future expectations.
- How do you interpret impairment of intangible assets?
- An increase is a negative signal indicating potential failure or reduced commercial prospects for specific pipeline assets.
- How does impairment of intangible assets compare across companies?
- Highly relevant in R&D-heavy industries where pipeline assets are frequently re-evaluated for commercial viability.